CBC (cannabichromene) and CBD (cannabidiol) are both non-intoxicating compounds found naturally in the cannabis plant. Neither one produces a high. They share some overlapping benefits, particularly around inflammation and seizures, but they work through different pathways in the body and have very different levels of research behind them. CBD is the more established of the two, with an FDA-approved medication to its name, while CBC is an emerging cannabinoid that shows promise but remains far less studied.
What Is CBD?
CBD is the most abundant non-intoxicating compound in cannabis. Unlike THC, its molecular structure contains a hydroxyl group instead of a cyclic ring, which is why it doesn’t produce psychoactive effects. CBD interacts with a remarkably wide range of receptors throughout the body. It activates serotonin receptors (specifically 5-HT1A), which plays a role in its anxiety-reducing effects. It also activates pain-sensing channels called TRPV1, binds partially to the CB2 receptor involved in immune function, and influences several other receptor systems tied to inflammation and nerve signaling.
The FDA has approved one CBD-based drug, Epidiolex, for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years and older. This remains the only cannabis-derived product with full FDA approval. CBD is also combined with THC in a 1:1 ratio in Sativex, approved in some countries for multiple sclerosis symptoms including pain and spasticity.
What Is CBC?
Cannabichromene is one of the “minor” cannabinoids, meaning it’s present in much smaller quantities in the plant. Most cannabis strains contain CBC at concentrations between 0.05% and 0.3% by weight, though some medical cannabis products have been formulated with up to 4% CBC. Like CBD, it does not activate the CB1 receptor, which is why it produces no high.
CBC works through a narrower set of targets than CBD. It acts on the CB2 receptor and on TRPA1, a channel involved in pain and inflammatory signaling. Notably, in studies on inflammation and swelling in mice, CBC’s anti-inflammatory effects were not mediated by either CB1 or CB2, suggesting it may reduce inflammation through a pathway researchers haven’t fully mapped yet. This makes it biologically interesting but also means there’s more uncertainty about exactly how it works.
How They Compare on Inflammation and Pain
Both CBC and CBD show anti-inflammatory activity, but the strongest evidence comes from using them together. In an arthritis study in mice, animals treated with both CBD and CBC showed significantly less swelling between weeks three and five compared to untreated controls. The combination produced a greater anti-inflammatory effect than either cannabinoid alone. This fits with a broader concept in cannabis science sometimes called the “entourage effect,” where multiple plant compounds amplify each other’s benefits.
When CBC was studied alongside THC for inflammation, researchers found an additive reduction in swelling. THC appeared to work through CB2 receptors, while CBC reduced inflammation through an entirely separate mechanism. This suggests CBC could complement other cannabinoids rather than duplicate what they already do.
How They Compare on Seizures
CBD’s anti-seizure properties are well established enough to support a prescription medication. CBC is much earlier in that journey, but initial results are noteworthy. In a mouse model of Dravet syndrome (a severe form of childhood epilepsy), CBC was as effective at reducing seizures as CBD. In a zebrafish model, CBC reduced seizures at a lower dose (1 µM) than CBD required (2 µM). These are preclinical findings in animal models, not clinical trials in humans, so they can’t be directly translated to dosing recommendations. But they suggest CBC has genuine anticonvulsant potential worth investigating further.
CBC and Brain Cell Growth
One area where CBC stands apart from CBD is its effect on nerve cells. When researchers exposed motor neuron-like cells to CBC at a concentration of 10 µM for 24 hours, the cells turned on a cluster of genes associated with neuronal maturation. Markers of nerve cell differentiation were activated, and the cells showed signs of structural remodeling, specifically the kind of internal scaffolding changes that happen when a cell is growing new connections. After 48 hours, these differentiation markers were still active, indicating the process was ongoing rather than a brief spike. Importantly, the cells were not turning into support cells (astroglia) but specifically into neurons. This has led to interest in CBC’s potential relevance to neurodegenerative conditions, though this work remains at the cellular level.
How Much CBC Is in Products
If you buy a broad-spectrum or full-spectrum CBD product, it likely contains small amounts of CBC, though the label may not specify how much. In one well-characterized medical cannabis oil used in a clinical study, the formulation contained 20 mg/mL of CBD alongside 1.1 mg/mL of CBC, roughly an 18:1 ratio. Dedicated CBC products do exist but are less common and less standardized than CBD products.
In the same clinical study, participants took daily doses of CBC ranging from 6.6 mg to 26.4 mg (always alongside CBD and small amounts of THC). At the highest dose, CBC was well-tolerated. One interesting pharmacokinetic finding: although the CBD dose was 18 times higher than the CBC dose, the body’s actual exposure to CBD was only about 7 to 10 times higher. This means CBC may be absorbed or metabolized more efficiently than CBD on a milligram-for-milligram basis, though more research is needed to confirm this.
Legal Status
Both CBC and CBD derived from hemp (cannabis containing less than 0.3% THC) are generally treated as legal under the 2018 Farm Bill at the federal level. State laws vary, and the regulatory landscape for hemp-derived cannabinoids continues to evolve. The FDA has not approved CBC in any form, and it has explicitly stated that no CBD products other than Epidiolex have received FDA approval, despite the wide availability of CBD oils, gummies, and topicals on the consumer market.
Key Differences at a Glance
- Research depth: CBD has decades of study and an FDA-approved drug. CBC research is mostly preclinical, conducted in animal models and cell cultures.
- Receptor targets: CBD interacts with over 20 known molecular targets. CBC primarily acts on CB2 and TRPA1, with some effects occurring through unknown pathways.
- Abundance in the plant: CBD is typically the dominant cannabinoid in hemp. CBC is present in trace to small amounts.
- Unique potential: CBC shows distinctive effects on nerve cell growth and differentiation that haven’t been reported for CBD.
- Combination benefits: The two appear to work better together for inflammation than either does alone.